We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DuPont Tops Earnings Estimates in Q4, Reports Flat Y/Y Sales
Read MoreHide Full Article
Key Takeaways
DD reported a 4Q25 loss from continuing ops, while its adjusted EPS beat estimates on flat sales.
DD's Healthcare & Water Technologies sales rose 4% y/y, offseting declines in Diversified Industrials.
DuPont projects $7.08-$7.14B in sales and an adjusted EPS of $2.25-$2.30 for 2026.
DuPont de Nemours, Inc. (DD - Free Report) has registered a fourth-quarter 2025 loss from continuing operations of $108 million or 27 cents per share. In the year-ago quarter, the company recorded a loss of $291 million or 70 cents per share.
Barring one-time items, earnings came in at 46 cents per share in the reported quarter, topping the Zacks Consensus Estimate of 43 cents.
DuPont's net sales reached $1,693 million, essentially flat year over year and surpassing the Zacks Consensus Estimate of $1,684.1 million. Organic sales fell 1%. Sales were flat, as a 1% year-over-year decrease in volume and flat pricing were offset by a positive foreign-currency impact of 1%.
DuPont de Nemours, Inc. Price, Consensus and EPS Surprise
The Healthcare & Water Technologies segment recorded net sales of $821 million in the reported quarter, up 4% on a year-over-year basis. Organic sales grew 3%, along with 1% benefit from currency. Healthcare Technologies delivered mid-single-digit organic growth, with strength in medical packaging and medical devices. Water Technologies sales rose in the low-single-digit range on an organic basis.
The Diversified Industrials segment recorded net sales of $872 million, down 3% year over year. Organic sales dipped 4% but were partially offset by a 1% benefit from currency. Building Technologies were down in the high-single-digit range on an organic basis due to weakness in construction markets. Industrial Technologies sales were down in the low-single-digit range on an organic basis.
DD’s Financials
DuPont had cash and cash equivalents of $715 million at the end of the quarter, down around 60% year over year. Long-term debt was $3,134 million, down about 41%.
The company generated an operating cash flow from continuing operations of $560 million for the year ended Dec. 31, 2025.
DD’s Outlook
For the first quarter of 2026, the company expects net sales of $1,670 million, operating EBITDA of $395 million and adjusted earnings per share (EPS) of 48 cents. For 2026, net sales are projected at $7,075-$7,135 million, with operating EBITDA estimated at $1,725-$1,755 million and adjusted EPS expected to be $2.25-$2.30.
DD’s Price Performance
DuPont’s shares have lost 42.2% in a year compared with a 13.5% decline in the industry.
Image Source: Zacks Investment Research
DD’s Zacks Rank & Stocks to Consider
DD currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the basic materials space are Albemarle Corporation (ALB - Free Report) , Coeur Mining, Inc. (CDE - Free Report) and Avino Silver & Gold Mines Ltd. (ASM - Free Report) .
Albemarle is slated to report fourth-quarter results on Feb. 11. The Zacks Consensus Estimate for earnings is pegged at a loss of 40 cents. ALB beat the Zacks Consensus Estimate in three of the last four quarters, while missing once, the average earnings surprise being 35.28%. ALB sports a Zacks Rank #1 (Strong Buy) at present. You can seethe complete list of today’s Zacks #1 Rank stocks here.
Coeur is scheduled to report fourth-quarter results on Feb. 18. The Zacks Consensus Estimate for CDE’s fourth-quarter earnings is pegged at 42 cents. CDE beat the Zacks Consensus Estimate in three of the last two quarters and missed once, the average earnings surprise being 106.61%. CDE currently flaunts a Zacks Rank #1.
Avino Silver is slated to report fourth-quarter results on March 11. The consensus estimate for ASM’s earnings is pegged at 6 cents. ASM, presently carrying a Zacks Rank #2 (Buy), beat the consensus estimate in the last four quarters, the average earnings surprise being 150%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
DuPont Tops Earnings Estimates in Q4, Reports Flat Y/Y Sales
Key Takeaways
DuPont de Nemours, Inc. (DD - Free Report) has registered a fourth-quarter 2025 loss from continuing operations of $108 million or 27 cents per share. In the year-ago quarter, the company recorded a loss of $291 million or 70 cents per share.
Barring one-time items, earnings came in at 46 cents per share in the reported quarter, topping the Zacks Consensus Estimate of 43 cents.
DuPont's net sales reached $1,693 million, essentially flat year over year and surpassing the Zacks Consensus Estimate of $1,684.1 million. Organic sales fell 1%. Sales were flat, as a 1% year-over-year decrease in volume and flat pricing were offset by a positive foreign-currency impact of 1%.
DuPont de Nemours, Inc. Price, Consensus and EPS Surprise
DuPont de Nemours, Inc. price-consensus-eps-surprise-chart | DuPont de Nemours, Inc. Quote
DD’s Segment Highlights
The Healthcare & Water Technologies segment recorded net sales of $821 million in the reported quarter, up 4% on a year-over-year basis. Organic sales grew 3%, along with 1% benefit from currency. Healthcare Technologies delivered mid-single-digit organic growth, with strength in medical packaging and medical devices. Water Technologies sales rose in the low-single-digit range on an organic basis.
The Diversified Industrials segment recorded net sales of $872 million, down 3% year over year. Organic sales dipped 4% but were partially offset by a 1% benefit from currency. Building Technologies were down in the high-single-digit range on an organic basis due to weakness in construction markets. Industrial Technologies sales were down in the low-single-digit range on an organic basis.
DD’s Financials
DuPont had cash and cash equivalents of $715 million at the end of the quarter, down around 60% year over year. Long-term debt was $3,134 million, down about 41%.
The company generated an operating cash flow from continuing operations of $560 million for the year ended Dec. 31, 2025.
DD’s Outlook
For the first quarter of 2026, the company expects net sales of $1,670 million, operating EBITDA of $395 million and adjusted earnings per share (EPS) of 48 cents. For 2026, net sales are projected at $7,075-$7,135 million, with operating EBITDA estimated at $1,725-$1,755 million and adjusted EPS expected to be $2.25-$2.30.
DD’s Price Performance
DuPont’s shares have lost 42.2% in a year compared with a 13.5% decline in the industry.
Image Source: Zacks Investment Research
DD’s Zacks Rank & Stocks to Consider
DD currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the basic materials space are Albemarle Corporation (ALB - Free Report) , Coeur Mining, Inc. (CDE - Free Report) and Avino Silver & Gold Mines Ltd. (ASM - Free Report) .
Albemarle is slated to report fourth-quarter results on Feb. 11. The Zacks Consensus Estimate for earnings is pegged at a loss of 40 cents. ALB beat the Zacks Consensus Estimate in three of the last four quarters, while missing once, the average earnings surprise being 35.28%. ALB sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Coeur is scheduled to report fourth-quarter results on Feb. 18. The Zacks Consensus Estimate for CDE’s fourth-quarter earnings is pegged at 42 cents. CDE beat the Zacks Consensus Estimate in three of the last two quarters and missed once, the average earnings surprise being 106.61%. CDE currently flaunts a Zacks Rank #1.
Avino Silver is slated to report fourth-quarter results on March 11. The consensus estimate for ASM’s earnings is pegged at 6 cents. ASM, presently carrying a Zacks Rank #2 (Buy), beat the consensus estimate in the last four quarters, the average earnings surprise being 150%.